Last reviewed · How we verify
Adapalene Lotion Vehicle
Adapalene is a third-generation retinoid that binds to retinoic acid receptors to normalize skin cell differentiation and reduce inflammation in acne.
Adapalene is a third-generation retinoid that binds to retinoic acid receptors to normalize skin cell differentiation and reduce inflammation in acne. Used for Acne vulgaris.
At a glance
| Generic name | Adapalene Lotion Vehicle |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Retinoid (third-generation) |
| Target | Retinoic acid receptors (RARγ, RARα, RARβ) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Adapalene selectively activates retinoic acid receptor gamma (RARγ) and other retinoid receptors, promoting keratinocyte differentiation and reducing comedone formation. It also exhibits anti-inflammatory properties by modulating cytokine production and immune cell activity in the skin. The lotion vehicle formulation is designed for topical delivery to improve tolerability and efficacy in acne treatment.
Approved indications
- Acne vulgaris
Common side effects
- Erythema
- Scaling/peeling
- Dryness
- Irritation
- Photosensitivity
Key clinical trials
- Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1% (PHASE3)
- Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1% (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adapalene Lotion Vehicle CI brief — competitive landscape report
- Adapalene Lotion Vehicle updates RSS · CI watch RSS
- Galderma R&D portfolio CI